Anesthetic Challenges in MEN2A Syndrome With Recurrent Pheochromocytoma: A Case Study

A case report published in the medical journal Cureus describes the successful anesthetic management of a patient with Multiple Endocrine Neoplasia Type 2A (MEN2A) who developed a recurrent pheochromocytoma on the contralateral adrenal gland. The report emphasizes that strict alpha-adrenergic blockade before surgery is essential to prevent life-threatening hypertensive crises during the removal of these catecholamine-secreting tumors, according to the study authors.

The patient documented in the June 24, 2026, report presented a complex clinical profile due to MEN2A, a hereditary condition that typically involves medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism. In this specific case, the patient had previously undergone surgery for a pheochromocytoma but later developed a new tumor on the opposite adrenal gland, a recurrence that significantly increased the risks associated with surgical anesthesia.

Why is anesthetic management critical for MEN2A patients?

Pheochromocytomas are tumors that secrete excessive amounts of catecholamines, such as adrenaline and noradrenaline. These hormones can cause sudden, severe spikes in blood pressure and heart rate, which are often triggered by the physical manipulation of the tumor during surgery, according to the Cureus report.

For patients with MEN2A, the risk is compounded because the syndrome often leads to bilateral tumors, meaning both adrenal glands may be affected. The authors note that the hemodynamic instability caused by a catecholamine storm can lead to myocardial infarction, stroke, or cardiac arrest if not managed with a precise pharmacological strategy.

The report highlights that the primary goal of the anesthesia team is to maintain stable blood pressure and heart rate throughout the induction of anesthesia and the surgical resection of the tumor.

How was the recurrent pheochromocytoma managed?

The medical team utilized a specific preoperative pharmacological sequence to stabilize the patient. This process began with alpha-adrenergic blockade, using medications to block the alpha receptors that cause blood vessels to constrict.

According to the case report, the sequence of medication is vital for the following reasons:

During the operation, the anesthesia team monitored the patient’s hemodynamic status in real-time. They used rapid-acting antihypertensive agents to counteract any spikes in blood pressure that occurred when the surgeon manipulated the adrenal mass.

What distinguishes MEN2A from sporadic pheochromocytoma?

Most pheochromocytomas are sporadic, meaning they occur randomly in a single gland. However, the Cureus report underscores that MEN2A is a genetic syndrome caused by mutations in the RET proto-oncogene. This genetic link makes the occurrence of bilateral tumors much more common than in sporadic cases.

The authors suggest that patients with known MEN2A require lifelong surveillance, as the risk of recurrence or the development of tumors in the other adrenal gland remains high even after an initial successful surgery. This necessitates a higher index of suspicion for clinicians when a patient presents with returning symptoms of hypertension or palpitations.

The report contrasts the management of this recurrent case with standard primary resections, noting that the patient’s previous surgical history and the nature of the genetic syndrome required a more vigilant approach to fluid management and blood pressure control.

What are the long-term implications for these patients?

The successful outcome of this case demonstrates that with meticulous preoperative preparation and intraoperative monitoring, high-risk MEN2A patients can safely undergo complex adrenalectomies. The study authors conclude that the combination of early diagnosis, appropriate alpha-blockade, and experienced anesthetic care reduces the morbidity associated with catecholamine-secreting tumors.

Medical professionals are encouraged to maintain a multidisciplinary approach, involving endocrinologists, surgeons, and anesthesiologists to manage the systemic nature of MEN2A. The report suggests that regular imaging and biochemical screening are the only ways to detect contralateral recurrences before they cause a clinical crisis.